CAPLIPOINTCaplin Point Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on CAPLIPOINT — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Revenue growth: 19.0% YoY
- • Profit growth: 19.4% YoY
- • ROE: 19.9%
- • RSI: 59
- • MACD: bullish
- • Price vs EMA21: above
Bull case
- • Revenue growth: 19.0% YoY
- • Profit growth: 19.4% YoY
- • ROE: 19.9%
- • RSI: 59
Bear case
- • Dividend yield: 0.28%
- • Volume: 0.4x 20-day average
- • Max drawdown (1y): 36%
Key risks
- • Dividend yield: 0.28%
- • Volume: 0.4x 20-day average
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹97.45). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.